You are viewing Allergic Living United States | Switch to Canada
Allergies, Asthma & Gluten-free

SIGN UP For Our Free e-Newsletter

Submit
Click To See Past Newsletters
Recalls

Allerject Recall Update: Sanofi Canada Instructs Customers to Return All Devices

20151028_C6278_PHOTO_EN_531746There is now sufficient supply of EpiPens to replace all Allerjects in Canada.

Sanofi Canada has released an update to its voluntary recall of Allerject devices that was originally made Oct. 28, 2015, saying that “Canadian customers are instructed to immediately return all Allerject devices to their local pharmacy.”

The company had originally asked pharmacists to limit replacing one epinephrine auto-injector per household until supplies of replacement EpiPen brand auto-injectors could be assured in sufficient quantities to meet replacement demand related to the recall. Last week, Pfizer Canada, which distributes the EpiPen and EpiPen Jr. devices in Canada told Allergic Living that the company would have sufficient supply of EpiPens to meet any increased demand due to the recall.

A spokesperson for Pfizer Canada said: “As of the week of November 23, we will be in a position to replenish all the recalled Allerject devices.”

In addition to advising Canadian Allerject owners that they can now return all the devices, in both the child (0.15 mg/0.15 mL) and adult (0.30 mg/0.3 mL) strengths, Sanofi Canada also notifies the public that:

  • Previous recommendations to limit the number of devices that can be replaced for an alternate auto-injector are now removed.
  • All Allerject epinephrine auto-injectors returned by patients to their pharmacist with an expiry date between October 2015 and December 2016 inclusively continue to be eligible for replacement at no cost to the patient.

Sanofi also wants to remind Canadian customers that “all Allerject devices were voluntarily recalled as they were found to potentially have inaccurate dosage delivery. If a patient who is experiencing a serious allergic reaction (i.e., anaphylaxis) did not receive the intended dose, there could be significant health consequences, including death because anaphylaxis is a potentially life-threatening condition.”

“This is a voluntary recall, but it’s still a recall,” Catherine Cunningham, a Sanofi Canada spokesperson, told Allergic Living. Urging Canadians to return any outstanding Allerject devices, she added: “There’s a reason why we made a decision to have a recall, because we’re unsure about the dosage delivery.”

People seeking more information about the Allerject recall can call the company directly: 1-855-405-4321.

To give us feedback on this article, please email comments@allergicliving.com

Close Close Free E-Letters From Allergic Living Free E-Letters From Allergic LivingFree E-Letters From Allergic Living